X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Versavo (bevacizumab) is a VEGF A inhibitor indicated for the treatment of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma & advanced cervical cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Versavo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Mirvetuximab was readily combined and well tolerated with standard dosing of carboplatin and bevacizumab, with a manageable adverse event (AE) profile as anticipated for this triplet based on the side effect profiles of each agent.
Lead Product(s): Mirvetuximab Soravtansine,Carboplatin,Bevacizumab
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
The combination of mirvetuximab soravtansine with bevacizumab in this cohort demonstrates encouraging anti-tumor activity with a favorable tolerability profile, particularly among the subset of patients with high levels of FRα expression.
Lead Product(s): Mirvetuximab Soravtansine,Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
EO2401 is a novel microbiome-derived therapeutic vaccine. It is being evaluated in combination with nivolumab & an anti-VEGF therapy bevacizumab for the treatment of patients with recurrent glioblastoma.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
Outlook Therapeutics intends to use the net proceeds to fund its ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an investigational ophthalmic formulation under development as an intravitreal injection for wet AMD and other retinal diseases.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Syntone Ventures
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 15, 2024
Details:
ME-344, an investigational drug candidate, is a novel inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) is being investigated in combination with bevacizumab in relapsed metastatic colorectal cancer patients.
Lead Product(s): ME-344,Bevacizumab
Therapeutic Area: Oncology Product Name: ME-344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
The proceeds will fund research and development of company's vaccine programs, including Granite, a personalized neoantigen-based vaccine, being evaluated in a Phase 2/3 study in patients with newly diagnosed, metastatic microsatellite-stable colorectal cancer.
Lead Product(s): GRT-C901,GRT-R902,Bevacizumab
Therapeutic Area: Oncology Product Name: Granite
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024
Details:
Granite (GRT-C901/GRT-R902) is patient-specific neoantigen cancer vaccine. It is being evaluated in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab for the treatment of front-line metastatic microsatellite stable colorectal cancer.
Lead Product(s): GRT-C901,GRT-R902,Bevacizumab
Therapeutic Area: Oncology Product Name: Granite
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
UTD1 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of breast cancer brain metastasis.
Lead Product(s): Utidelone,Bevacizumab,Etoposide
Therapeutic Area: Oncology Product Name: UTD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
ONS-5010 (bevacizumab) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
Outlook Therapeutics intends to use the net proceeds to fund its ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an investigational ophthalmic formulation under development as an intravitreal injection for wet AMD and other retinal diseases.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $159.0 million Upfront Cash: $60.0 million
Deal Type: Private Placement March 18, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
GEN-1 (IMNN-001) is a DNA-based interleukin-12 (IL-12) immunotherapy, which is being evaluated in combination with bevacizumab for the treatement of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: GEN-1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Under the collaboration, Roche will conduct clinical trial studies to evaluate the safety, efficacy of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.
Lead Product(s): IO-108,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2024
Details:
ONS-5010 (bevacizumab-vikg) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated in phase 3 cliical trials for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Outlook Therapeutics intends to use the proceeds to fund its ONS-5010/Lytenava, an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD, including to initiate and fund the planned NORSE EIGHT trial.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Great Point Partners
Deal Size: $172.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 23, 2024
Details:
Transarterial Chemoembolization (TACE) in combination with Imfinzi (Durvalumab) and Bevacizumab is being evaluated in phase 3 clinical trials for the treatment of Hepatocellular Carcinoma.
Lead Product(s): Durvalumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2024
Details:
Under the agreement, Merck will receive an exclusive license to RGX-202 (ompenaclid), currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer, outside of the United States and an option to co-develop and co-promote ompenaclid in the US.
Lead Product(s): RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: RGX-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: $45.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
ONS-5010 (bevacizumab-biosimilar) is a VEGF-A inhibitor antibody which is being evaluated in phase 3 clinical trials for the treatment of neovascular age-related macular degeneration & wet macular degeneration,
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care Tecentriq (atezolizumab) and Avastin (bevacizumab) in first-line treatment of unresectable/advanced hepatocellular carcinoma.
Lead Product(s): NKT2152,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2023
Details:
FDA has approved Avzivi® (bevacizumab-tnjn), a biosimilar humanized monoclonal antibody that binds and inhibits VEGF, for the treatment for lung and colorectal cancers.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Avzivi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
ONS-5010 (bevacizumab-vikg) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated in phase 3 cliical trials for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Lead Product(s): Durvalumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
ONS-5010 ((bevacizumab-vikg) is an investigational ophthalmic formulation which is act as vascular endothelial growth factor inhibitor and investigated for the treatment of wet AMD.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) and platinum-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (PFS).
Lead Product(s): Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that is investigated in combination with bevacizumab for the treatment of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR alpha antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for unresectable or metastatic hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
ONS-5010 ((bevacizumab-vikg) is an investigational ophthalmic formulation which is act as vascular endothelial growth factor inhibitor and investigated for the treatment of wet AMD.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Lead Product(s): Denifanstat,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ascletis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in Combined with Bevacizumab for Treatment of Recurrent Glioblastoma.
Lead Product(s): ASC40,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388 (casdozokitug), a novel IL-27-targeted antibody being evaluated in Phase 2 in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): Casdozokitug,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $66.9 million Upfront Cash: $26.9 million
Deal Type: Acquisition September 08, 2023
Details:
ME-344 is a novel mitochondrial inhibitor targeting energy production through the OXPHOS pathway evaluating in combination with bevacizumab in patients with previously treated metastatic colorectal cancer.
Lead Product(s): ME-344,Bevacizumab
Therapeutic Area: Oncology Product Name: ME-344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Onvansertib,Bevacizumab,Calcium Folinate
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Lonsurf (trifluridine/tipiracil), an oral nucleoside antitumor agent, got approved as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC).
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
DKN-01, is an anti-Dickkopf-1 (DKK1) antibody and in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced CRC.
Lead Product(s): Sirexatamab,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
Bevacizumab is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Avastin-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
The company intends to use the net proceeds for its pipeline development including, IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388, a novel IL-27-targeted antibody being evaluated in Phase 2 trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): SRF388,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $65.0 million Upfront Cash: $25.0 million
Deal Type: Acquisition June 16, 2023
Details:
Genelux will use the net proceeds for advancement of clinical programs, including the Phase 3 registrational trial of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, non-pathogenic oncolytic vaccinia virus, in patients with platinum-resistant/refractory ovarian cancer.
Lead Product(s): Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 12, 2023
Details:
IGM-8444 is an IgM antibody targeting death receptor 5 (DR5) that is being developed for the treatment of patients with solid tumor including metastatic colorectal cancerand hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adagene Suzhou Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
TPST-1120 target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a monotherapy or in combination with other approved agents.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Lonsurf consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, it has demonstrated anti-tumor activity against refractory colorectal cancer, in combination with bevacizumab.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.
Lead Product(s): Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2023
Details:
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 has an important role in mediating an immune suppressive tumor microenvironment and in promoting tumor proliferation, metastasis, and angiogenesis.
Lead Product(s): DKN-01,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
The financing will be used for further strengthening the company’s pipeline and portfolio especially in Oncology area. Etana will produce Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients in Indonesia.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Yunfeng Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 20, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein which is one of the most active cytokines for the induction of potent anticancer immunity.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Break Through Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Cosela (Trilaciclib) is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.
Lead Product(s): Trilaciclib,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Lead Product(s): NP137,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NP137
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
